Our Expertise. Your Advantage.

2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Real-world outcomes among Medicare beneficiaries treated with first-line (1L) Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL)

Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2026

High- or Moderate-Efficacy Treatment Sequence and Patterns Among People with Relapsing-Remitting Multiple Sclerosis in the United States: A Retrospective Cohort Study

CMSC 2026

Treatment Patterns of Ocrelizumab Subcutaneous: An Early Look Into Utilization in a Medicare Population With Multiple Sclerosis

ISPOR 2026

An AI-Driven Random Survival Forest Model for Predicting Cancer-Specific Survival in Pediatric Neuroblastoma: A SEER Analysis

ISPOR 2026

Expert Consensus on Treatment Guidance for FDA-Approved and Second-Generation Exon-Skipping Therapies in Duchenne Muscular Dystrophy (DMD): a RAND/UCLA Modified Delphi Panel

White Paper in Collaboration with Crabgrass & Clover, LLC

Understanding Drug Spend Patterns Among Non-Low Income (NLIS) MAPD Plan Switchers

American Academy of Neurology (AAN) Annual Meeting 2026

A Retrospective Cohort Study to Assess the Clinical and Economic Burden in Treated versus Untreated People with Relapsing-Remitting Multiple Sclerosis in the United States

American Academy of Neurology (AAN) Annual Meeting 2026

Clinical and Economic Impact and Treatment Patterns in People with Secondary Progressive Multiple Sclerosis: A Retrospective Cohort Study in the United States

Analysis of 340B modifier usage in Medicare Part D claims for IPAY 2026 and IPAY 2027 selected drugs

Journal of Geriatric Oncology

Real-world patterns of maintenance therapy after allogeneic transplant in older adults with acute myeloid leukemia: A Medicare cohort study

Journal of Ocular Pharmacology and Therapeutics

Systematic Literature Review on the Effect of Cenegermin on Corneal Sensation and Innervation in Patients with Neurotrophic Keratopathy

MDA Clinical & Scientific Conference

Expert Consensus on Dystrophin and Creatine Kinase as Predictors of Clinical Benefit in Duchenne Muscular Dystrophy: a RAND/UCLA Modified Delphi Panel